# BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:

Case No. 5413

OPTUMRX INC., DBA OPTUMRX 2858 Loker Avenue East, Ste. 100 Carlsbad, CA 92010

STIPULATED SETTLEMENT AND DISCIPLINARY ORDER FOR PUBLIC REPROVAL

**Pharmacy Permit Number PHY 47482** 

PHONG QUOC LY 2858 Loker Avenue East, Ste. 100 Carlsbad, CA 92010

Pharmacist License No. RPH 51836

Respondents.

### **DECISION AND ORDER**

The attached Stipulated Settlement and Disciplinary Order for Public Reproval is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on January 23, 2017.

It is so ORDERED on December 23, 2016.

BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

By

Amy Gutierrez, Pharm.D. Board President

1 2	KAMALA D. HARRIS Attorney General of California GREGORY J. SALUTE		
3	Supervising Deputy Attorney General DESIREE I. KELLOGG		
4	Deputy Attorney General State Bar No. 126461		
5	600 West Broadway, Suite 1800 San Diego, CA 92101	· 	
6	P.O. Box 85266 San Diego, CA 92186-5266		
7	Telephone: (619) 738-9429 Facsimile: (619) 645-2061		
8	Attorneys for Complainant	;	
	11	RE THE	
9	BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS		
10	STATE OF CALIFORNIA		
11	In the Matter of the Accusation Against:	Case No. 5413	
12	OPTUMRX INC., DBA OPTUMRX	STIPULATED SETTLEMENT AND	
13	2858 Loker Avenue East, Ste. 100 Carlsbad, CA 92010	DISCIPLINARY ORDER FOR PUBLIC REPROVAL	
14	Pharmacy Permit No. PHY 47482	[Bus. & Prof. Code § 495]	
15	PHONG QUOC LY	3	
16 17	2858 Loker Ave East, Ste. 100 Carlsbad, CA 92010		
18	Pharmacist License No. RPH 51836		
19	Respondents.		
20			
21			
22	IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-		
23	entitled proceedings that the following matters as	e true:	
24	<u>PARTIES</u>		
25	1. Virginia K. Herold (Complainant) is the Executive Officer of the Board of Pharmacy.		
26	She brought this action solely in her official capa	city and is represented in this matter by Kamala	
27	D. Harris, Attorney General of the State of California, by Desiree I. Kellogg, Deputy Attorney		
28	General.		
	. 1		

documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.

8. Respondents voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.

#### CULPABILITY.

- 9. Respondents understand and agree that the charges and allegations in Accusation No. 5413, if proven at a hearing, constitute cause for imposing discipline upon their respective Pharmacy Permit and Pharmacist License.
- 10. For the purpose of resolving the Accusation without the expense and uncertainty of further proceedings, Respondents agree that, at a hearing, Complainant could establish a factual basis for the charges in the Accusation, and that Respondents hereby give up their right to contest those charges.
- 11. Respondent OptumRx agrees that its Pharmacy Permit is subject to discipline and Respondent Phong Ly agrees that his Pharmacist License is subject to discipline and they agree to be bound by the Disciplinary Order below.

## <u>CONTINGENCY</u>

- 12. This stipulation shall be subject to approval by the Board of Pharmacy. Respondents understand and agree that counsel for Complainant and the staff of the Board of Pharmacy may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondents or their counsel. By signing the stipulation, Respondents understand and agree that they may not withdraw their agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order for Public Reproval shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.
- 13. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order for Public Reproval, including

Portable Document Format (PDF) and facsimile signatures thereto, shall have the same force and effect as the originals.

- 14. This Stipulated Settlement and Disciplinary Order for Public Reproval is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order for Public Reproval may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.
- 15. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

# **DISCIPLINARY ORDER**

IT IS HEREBY ORDERED that Pharmacy Permit No. PHY 47482 issued to Respondent OptumRx Inc., doing business as OptumRx (Optum Rx) and Pharmacist License No. RPH 51836 issued to Respondent Phong Quoc Ly (Phong Quoc Ly) shall be publicly reproved by the Board of Pharmacy under Business and Professions Code section 495 based on the allegations set forth in Accusation No. 5413 which is attached hereto as Exhibit A and incorporated by reference as though fully set forth herein.

IT IS FURTHER ORDERED that OptumRx shall comply with the terms and conditions as set forth below. Any violation of the terms and conditions shall constitute unprofessional conduct and grounds for further disciplinary action.

IT IS FURTHER ORDERED that OptumRx shall pay \$7,930.25 to the Board for its costs associated with the investigation and enforcement of this matter. OptumRx shall be permitted to pay these costs in a payment plan approved by the Board. If OptumRx fails to pay the Board costs as ordered, OptumRx shall not be allowed to renew its Pharmacy Permit until OptumRx pays costs in full.

IT IS FURTHER ORDERED that within sixty (60) days of the effective date of this 1 decision, OptumRx shall submit to the Board or its designee, for prior approval, a community 2 3 service program in which OptumRx shall provide free sharp disposal containers or provide free or at a reduced cost immunizations, brown bag consultations, or other healthcare related services to 4 a community, charitable facility or agency valuing \$20,000.00. Within thirty (30) days of board 5 approval thereof, OptumRx shall submit documentation to the Board demonstrating 6 commencement of the community service program. OptumRx shall complete the community service program and report on that completion to the board within six (6) months of the effective 8 date of the decision. ġ ACCEPTANCE 10 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public Reproval and have fully discussed it with my attorney, Edward D. Rickert. I understand the 12 stipulation and the effect it will have on my Pharmacist License. I enter into this Stipulated Settlement and Disciplinary Order for Public Reproval voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy. Respondent

11

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1	I am authorized to sign on behalf of OptumRx Inc., doing business as OptumRx. I have		
2	carefully read the above Stipulated Settlement and Disciplinary Order for Public Reproval and		
3	have fully discussed it with my attorney, Edward D. Rickert. I understand the stipulation and the		
4	effect it will have on the Pharmacy Permit. On behalf of OptumRx Inc., doing business as		
5	OptumRx, I enter into this Stipulated Settlement and Disciplinary Order for Public Reproval		
6	voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the		
7	Board of Pharmacy.		
8			
9	DATED: Bril. Wyce		
10	BRIAN WENGER General Counsel, Optum, Inc. and Authorized Agent		
11	for OPTUMRX INC., DBA OPTUMRX		
12	I have read and fully disapposed with Doorsendant Out. D. J.		
13	I have read and fully discussed with Respondent OptumRx Inc., doing business as		
14	OptumRx and Phong Quoc Ly the terms and conditions and other matters contained in the above		
15	Stipulated Settlement and Disciplinary Order for Public Reproval. I approve its form and content.		
16	DATED:		
17	EDWARD D. RICKERT		
18	Attorney for Respondent //		
19			
20			
21	· · · · · · · · · · · · · · · · · · ·		
22	$\frac{1}{2}$		
23			
24			
4"1			
25			
l			
25			
25 26	// // // // // // // // // // // // //		

# ENDORSEMENT The foregoing Stipulated Settlement and Disciplinary Order for Public Reproval is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs. DATED: Respectfully submitted, KAMALA D. HARRIS Attorney General of California GREGORY J. SALUTE Supervising Deputy Attorney General DESIREE I. KELLOGG Deputy Attorney General Attorneys for Complainant

SD2015700511 81404084.doc

Exhibit A

Accusation No. 5413

1	KAMALA D. HARRIS	
2	Attorney General of California GREGORY J. SALUTE	
3	Supervising Deputy Attorney General DESIREE I. KELLOGG	
4	Deputy Attorney General State Bar No. 126461	
5	110 West "A" Street, Suite 1100 San Diego, CA 92101	
6	P.O. Box 85266 San Diego, CA 92186-5266	
7	Telephone: (619) 645-2996 Facsimile: (619) 645-2061	
8	Attorneys for Complainant	
9	BEFORE THE BOARD OF PHARMACY	
10	DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA	
11		
12	In the Matter of the Accusation Against: Case No. 5413	
13	OPTUMRX INC., DBA OPTUMRX 2858 Loker Avenue East, Ste. 100 Carlsbad, CA 92010  A C C U S A T I O N	
14	Pharmacy Permit No. PHY 47482	
15	PHONG QUOC LY	
16	2858 Loker Ave East, Ste. 100 Carlsbad, CA 92010	
17	Pharmacist License No. RPH 51836	
18	Respondents.	
19		
20		
21	Complainant alleges:	
22	PARTIES	
23	1. Virginia Herold (Complainant) brings this Accusation solely in her official capacity	
24	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.	
25	2. On or about March 22, 2006, the Board of Pharmacy issued Pharmacy Permit	
26	Number PHY 47482 to OptumRx Inc., doing business as OptumRx (Respondent OptumRx). The	
27	Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein	
28	and will expire on March 1, 2017, unless renewed.	

3. On or about August 30, 2000, the Board of Pharmacy issued Pharmacist License Number RPH 51836 to Phong Quoc Ly (Respondent Phong Ly). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on November 30, 2017, unless renewed.

#### JURISDICTION

- 4. This Accusation is brought before the Board of Pharmacy (Board), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.
- 5. Section 4011 of the Code provides that the Board shall administer and enforce both the Pharmacy Law [Bus. & Prof. Code, § 4000 et seq.] and the Uniform Controlled Substances Act [Health & Safety Code, § 11000 et seq.].
  - 6. Section 4113(c) of the Code states:

The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.

- 7. Section 4300(a) of the Code provides that every license issued by the Board may be suspended or revoked.
  - 8. Section 4300.1 of the Code states:

The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.

# STATUTORY AND REGULATORY PROVISIONS

9. Section 733(a) states:

A licentiate shall not obstruct a patient in obtaining a prescription drug or device that has been legally prescribed or ordered for that patient. A violation of this section constitutes unprofessional conduct by the licentiate and shall subject the licentiate to disciplinary or administrative action by his or her licensing agency.

10. Section 4301 of the Code states in pertinent part:

The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or any other state or federal regulatory agency.

#### COST RECOVERY

11. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

#### **DRUGS**

- 12. Atripla is the brand name for a combination of the generic drugs, efavirenz, emtricitabine and tenofovir and is a dangerous drug pursuant to Business and Professions Code section 4022. It is utilized to treat Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS).
- 13. <u>Lipitor</u> is the brand name for atorvastatin and is a dangerous drug pursuant to Business and Professions Code section 4022. It is utilized to treat hypercholesteremia.
- 14. <u>Singulair</u> is the brand name for montelukast and is a dangerous drug pursuant to Business and Professions Code section 4022. It is utilized to treat asthma and prevent allergy symptoms.
- 15. Zetia is the brand name for ezetimibe and is a dangerous drug pursuant to Business and Professions Code section 4022. It is utilized to treat hypercholesteremia.

## **FACTUAL ALLEGATIONS**

16. At all relevant times herein, Respondent dispensed prescription drugs to patients via mail or overnight delivery services. From February 20, 2012 through the present, Respondent Phong Ly was the Pharmacist-in-Charge of Respondent OptumRx.

## Patient Christopher O.

- 17. On or about August 23, 2013, Dr. Timothy A. prescribed Atripla 600 mg-200 mg-300 mg with the instructions to take one tablet per day, in a quantity of 30 for a 30 day supply with 11 refills to patient Christopher O. On or about March 19, 2014, patient Christopher O. ordered a refill of Prescription Number 100407835, Atripla, 600 mg-200 mg-300 mg tablets in a quantity of 30 tablets for a 30 day supply, from Respondents who informed him that he would receive his refill on March 21, 2014. Respondents did not furnish the refill for Atripla on March 21, 2014. Instead, Respondents initiated the dispensing process for a refill order in the quantity of 90 tablets for a 90 day supply which caused the order to be placed on hold for prior insurance authorization. Respondents then cancelled the refill order.
- 18. On March 21, 2014, patient Christopher O. contacted Respondents to inquire about the status of his refill. Respondents informed him that his refill would be delivered to him on March 24, 2014. However, Respondents did not dispense or furnish the refill on March 24, 2014, resulting in a delay in the furnishing of a drug which the patient needed to take every day. Instead, the prescription was delivered on March 25, 2014.

#### Patient Suzanne S.

- 19. On or about May 23, 2014, Dr. Christopher M. prescribed 90 tablets of Zetia with directions to take 1 tablet daily with 3 additional refills. On or about August 19, 2014, patient Suzanne S. requested a refill of her prescription for Zetia 10 mg from Respondent. On the order form, she requested that the medication be delivered to an alternate address. Respondents processed her order and charged her credit card shortly thereafter. Suzanne S. did not receive her medication.
- 20. On August 30, 2014, Suzanne S. contacted Respondents to inquire about the status of her medication. She was informed that her medication had not been sent to her alternative address and that her medication would be reshipped to her. Suzanne S. did not receive her medication.
- 21. On September 9, 2014, Suzanne S.'s husband contacted Respondents again to inquire about the status of her medication. He was informed that another error had occurred and her

medication had not shipped. He was promised that it would be shipped via an overnight delivery service and delivered by September 10 or 11, 2014. Suzanne S. did not receive her medication.

- 22. On September 12, 2014, Suzanne S.'s husband contacted Respondents. He was informed that Respondents would attempt to arrange for the medication to be delivered expeditiously on a Saturday and that an individual from "corporate" would contact her regarding her medication within 24 hours. Suzanne S. did not receive her medication nor did anyone from "corporate" contact her.
- 23. On September 13, 2014, Suzanne S.'s husband received a telephone call from Respondents who told her that her medication would be shipped possibly on September 15, 2014. On September 16, 2014, Suzanne S. received her medication from Respondents.

## Patient Jody M.

- 24. On January 30, 2015, patient Jody M. requested that Respondents obtain a new prescription for Lipitor 40mg from her physician, Dr. Anna S. Respondents did not receive a response from Dr. Anna S to their request for a new prescription. On February 16, 2016, Jody M. contacted Respondents to inquire about the status of her medication. She was informed that her physician did not respond to the request for a new prescription. On February 17, 2015, she contacted Respondents to request that another request for the new prescription be sent to Dr. Anna S. Respondents' pharmacy clerk told Jody M. that another request would be sent to Dr. Anna S. However, it was not sent to Dr. Anna S. nor was Jody M advised of the status of her medication.
- 25. On February 24, 2015, Jody M. contacted Respondents because she had not received her medication. Respondents issued yet another new prescription request to Dr. Anna S. On February 27, 2015, Jody M. received her medication from Respondents.

#### Patient Anne M.

26. On February 9, 2015, patient Anne M.'s physician, Dr. Kevin B. transmitted a prescription for Singulair 10mg to Respondents. On February 10, 2015, Anne M. contacted Respondents to confirm that they had received the prescription for Singulair. She was told they had received it and her medication would ship shortly. Anne M. did not receive her medication.

27. On February 16, 2015, Anne M. contacted Respondents and was told her medication would be delivered by February 19, 2015. On February 18, 2015, Anne M. contacted Respondents and was told her medication would be delivered by February 20, 2015. On February 23, 2015, Anne M. received her medication from Respondents.

FIRST CAUSE FOR DISCIPLINE

# (Obstructing Patients in Obtaining Prescription Drugs)

28. Respondents are subject to disciplinary action under Code section 4301(o), for violating Code section 733(a) in that they obstructed patients from obtaining their prescription drugs, as set forth in paragraphs 12 through 27 above, which are incorporated herein by reference.

# SECOND CAUSE FOR DISCIPLINE

# (Unprofessional Conduct)

29. Respondents are subject to disciplinary action under Code section 4301 for unprofessional conduct in that they engaged in the activities described in paragraphs 12 through 27 above, which are incorporated herein by reference.

## **DISCIPLINARY CONSIDERATIONS**

- 30. To determine the degree of discipline, if any, to be imposed on Respondents, Complainant alleges that:
- a. On April 8, 2015, the Board issued Citation number CI 2014 64973 against Respondent Phong Ly for violating Business and Professions Code section 733(a) in that she obstructed the dispensing of prescription drugs. The Board issued a fine which Respondent Phong Ly paid.
- b. On February 18, 2015, the Board issued Citation number CI 2014 64283 against Respondent Phong Ly for violating Business and Professions Code section 733(a) in that she obstructed the dispensing of prescription drugs. The Board issued a fine which Respondent Phong Ly paid.
- c. On February 9, 2015, the Board issued Citation number CI 2014 64192 against Respondent Phong Ly for incompetence in violation of Business and Professions Code section 4301(b). The Board issued a fine which Respondent Phong Ly paid.

- d. On July 9, 2014, the Board issued Citation number CI 2013 59891 against Respondent OptumRx for violating Business and Professions Code section 733(a) in that it obstructed the dispensing of prescription drugs.
- e. On January 23, 2014, the Board issued Citation number CI 2012 54362 against Respondent OptumRx for violating Business and Professions Code section 733(a) in that it obstructed the dispensing of prescription drugs and devices and California Code of Regulations, title 16, section 1716 for deviating from the requirements of a prescription without the prior consent of the prescriber. The Board issued a fine which Respondent OptumRx paid.
- f. On April 11, 2014, the Board issued Citation number CI 2013 60829 against Respondent Phong Ly for violating Civil Code section 56.10(a) and California Code of Regulations, title 16, section 1764 in that there was the unauthorized release of protected healthcare information.
- g. On April 11, 2014, the Board issued Citation number CI 2013 58107 against Respondent OptumRx for violating Civil Code section 56.10(a) and California Code of Regulations, title 16, section 1764 in that there was the unauthorized release of protected healthcare information. The Board issued a fine which Respondent OptumRx paid.
- h. On July 9, 2014, the Board issued Citation number CI 2013 59891 against Respondent OptumRx for violating Business and Professions Code section 733(a) in that it obstructed the dispensing of prescription drugs. The Board issued a fine which Respondent OptumRx paid.
- i. On February 14, 2013, the Board issued Citation number CI 2012 53121 against Respondent OptumRx for violating California Code of Regulations, title 16, section 1716 in that it dispensed a prescription without clarifying the dose with the prescriber. The Board issued a fine which Respondent OptumRx paid.
- j. On November 15, 2013, the Board issued Citation number CI 2012 56693 against Respondent OptumRx for violating Business and Professions Code section 733(a) in that it obstructed the dispensing of prescription drugs. The Board issued a fine which Respondent OptumRx paid.

71035213.doc